Recap: AtriCure Q2 Earnings

Shares of AtriCure ATRC were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 123.53% over the past year to ($0.38), which beat the estimate of ($0.61).

Revenue of $40,824,000 decreased by 30.70% from the same period last year, which beat the estimate of $35,450,000.

Looking Ahead

AtriCure hasn't issued any earnings guidance for the time being.

AtriCure hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Jul 28, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/5q5jzg3q

Technicals

52-week high: $51.76

Company's 52-week low was at $22.57

Price action over last quarter: Up 3.59%

Company Overview

AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.